Trevena Company Profile (NASDAQ:TRVN)

About Trevena (NASDAQ:TRVN)

Trevena logoTrevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TRVN
  • CUSIP: N/A
  • Web: www.trevenainc.com
Capitalization:
  • Market Cap: $139.92 million
  • Outstanding Shares: 58,301,000
Average Prices:
  • 50 Day Moving Avg: $2.83
  • 200 Day Moving Avg: $4.51
  • 52 Week Range: $2.15 - $8.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.54
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.88 million
  • Price / Sales: 74.12
  • Book Value: $1.18 per share
  • Price / Book: 2.03
Profitability:
  • EBIDTA: ($105,200,000.00)
  • Return on Equity: -117.85%
  • Return on Assets: -86.74%
Debt:
  • Debt-to-Equity Ratio: 0.36%
  • Current Ratio: 9.13%
  • Quick Ratio: 9.13%
Misc:
  • Average Volume: 626,202 shs.
  • Beta: -0.58
  • Short Ratio: 7.49
 

Frequently Asked Questions for Trevena (NASDAQ:TRVN)

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.19. View Trevena's Earnings History.

When will Trevena make its next earnings announcement?

Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Trevena.

Where is Trevena's stock going? Where will Trevena's stock price be in 2017?

11 analysts have issued twelve-month price targets for Trevena's shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Trevena's share price to reach $11.73 in the next year. View Analyst Ratings for Trevena.

What are analysts saying about Trevena stock?

Here are some recent quotes from research analysts about Trevena stock:

  • 1. Needham & Company LLC analysts commented, "Trevena announced 1Q17 financial results yesterday. Olinvo NDA submission in pain still on track for 4Q17. Phase 3 open-label ATHENA safety trial has reached 600pt enrollment. Company therefore likely to reach target 1100 pt exposures per FDA recommendation (~480pts treated in APOLLO trials) in near future. As a reminder, Olinvo Phase 3 APOLLO trials did not establish consistent statistically significant differentiation from morphine on secondary GI and respiratory endpoints. We believe observed trend was clinically meaningful, but have updated our models to reflect modest market penetration given likely challenges in communicating differentiation." (5/5/2017)
  • 2. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (3/29/2017)
  • 3. Cowen and Company analysts commented, "TRVN reported 4Q16 results." (3/22/2017)
  • 4. HC Wainwright analysts commented, "Following the Phase 3 pivotal APOLLO readouts, and the subsequent ~45% drop in TRVN shares (vs. -1.5% NBI) over the last two trading sessions, we assess the implications of the mixed data set, and suggest likely/ probable clinical settings for use that best match OLINVO's (new brand name for oliceridine) overall therapeutic profile' we believe some physicians may find OLINVO useful at reducing antiemetic use, especially in hard tissue pain (most commonly, knee and hip surgery). Yet despite a more nuanced view than some, we nonetheless acknowledge that APOLLO results are far from the "clean win" we were hoping for." (2/23/2017)
  • 5. Aegis analysts commented, "After presenting results yesterday, Trevena finished the trading day down approximately 40%. We believe there are several contributing factors: (1) the lowest dose 0.1 mg did not prove non-inferiority to that of morphine; (2) on the safety side, improvements on the respiratory and nausea/vomiting measurement did not show statistical significance to that of Morphine; (3) investors may think that the current data set points to an Oliceridine that has no commercial value proposition relative to that of morphine. This could lead to slow market adoption; (4) the company may need a capital raise before the NDA is accepted. If a capital raise is completed with current share price, this may lead to excessive dilution; (5) the Athena open label study may be a little behind schedule which puts further pressure on cash runway of the company. We will be buyers on weakness. We view the situation quite differently. The most important thing in our eye's is that Trevena is likely to have enough data for an NDA in 4Q17 after the Athena trial is completed." (2/22/2017)

Who are some of Trevena's key competitors?

Who are Trevena's key executives?

Trevena's management team includes the folowing people:

  • Leon O. Moulder Jr., Independent Chairman of the Board
  • Maxine Gowen Ph.D., President, Chief Executive Officer, Director
  • Roberto E. Cuca, Chief Financial Officer, Senior Vice President
  • Michael W. Lark Ph.D., Senior Vice President - Research, Chief Scientific Officer
  • John M. Limongelli Esq., Senior Vice President, General Counsel, Corporate Secretary
  • Carrie L Bourdow, Senior Vice President, Chief Commercial Officer
  • Yacoub Habib Ph.D., Senior Vice President - Business Development and Corporate Planning
  • David Soergel M.D., Senior Vice President - Clinical Development , Chief Medical Officer
  • Michael R. Dougherty, Independent Director
  • Adam M. Koppel M.D. Ph.D., Independent Director

Who owns Trevena stock?

Trevena's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (12.85%), FMR LLC (12.32%), NEA Management Company LLC (6.67%), Polaris Venture Management Co. V L.L.C. (3.52%), Vanguard Group Inc. (2.77%) and Northpointe Capital LLC (2.04%). Company insiders that own Trevena stock include Carrie L Bourdow, David Soergel, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.

Who sold Trevena stock? Who is selling Trevena stock?

Trevena's stock was sold by a variety of institutional investors in the last quarter, including HarbourVest Partners LLC, Russell Investments Group Ltd., Credit Suisse AG, Bourgeon Capital Management LLC, ProShare Advisors LLC, TIAA CREF Investment Management LLC and United Services Automobile Association. View Insider Buying and Selling for Trevena.

Who bought Trevena stock? Who is buying Trevena stock?

Trevena's stock was bought by a variety of institutional investors in the last quarter, including Northpointe Capital LLC, Paulson & CO. Inc., Palo Alto Investors LLC, FMR LLC, Highbridge Capital Management LLC, Sphera Funds Management LTD., Dimensional Fund Advisors LP and Vanguard Group Inc.. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Insider Buying and Selling for Trevena.

How do I buy Trevena stock?

Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trevena's stock price today?

One share of Trevena stock can currently be purchased for approximately $2.39.


MarketBeat Community Rating for Trevena (NASDAQ TRVN)
Community Ranking:  4.2 out of 5 (   )
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Trevena (NASDAQ:TRVN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.73 (390.68% upside)

Analysts' Ratings History for Trevena (NASDAQ:TRVN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Needham & Company LLCBoost Price TargetBuy$9.00 -> $11.00LowView Rating Details
5/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
5/6/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
5/4/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$10.00MediumView Rating Details
4/17/2017AegisReiterated RatingBuy$14.00LowView Rating Details
3/22/2017Cowen and CompanyReiterated RatingBuy$13.00LowView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$8.00HighView Rating Details
2/16/2017Jefferies Group LLCReiterated RatingBuy$11.00N/AView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$15.00N/AView Rating Details
12/1/2016WedbushReiterated RatingOutperform$16.00N/AView Rating Details
10/25/2016Brean CapitalSet Price TargetBuy$14.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00N/AView Rating Details
3/2/2016WallachBeth CapitalInitiated CoverageBuy$18.00N/AView Rating Details
2/24/2016Barclays PLCLower Price TargetOverweight$18.00 -> $15.00N/AView Rating Details
(Data available from 6/29/2015 forward)

Earnings

Earnings History for Trevena (NASDAQ:TRVN)
Earnings by Quarter for Trevena (NASDAQ:TRVN)
Earnings History by Quarter for Trevena (NASDAQ TRVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/4/2017Q1 2017($0.55)($0.36)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.62)($0.67)$0.48 millionViewListenView Earnings Details
11/3/2016Q3 2016($0.40)($0.57)$1.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.35)$1.93 million$1.88 millionViewN/AView Earnings Details
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details
11/10/2015Q3($0.34)($0.24)$1.80 million$1.88 millionViewN/AView Earnings Details
8/11/2015Q215($0.37)($0.28)$1.30 million$1.88 millionViewN/AView Earnings Details
5/7/2015($0.33)($0.33)$10.00 million$0.63 millionViewN/AView Earnings Details
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details
5/9/2014Q114($0.36)($0.59)$0.03 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Trevena (NASDAQ:TRVN)
2017 EPS Consensus Estimate: ($1.64)
2018 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.38)($0.48)
Q2 20174($0.54)($0.36)($0.43)
Q3 20174($0.50)($0.21)($0.37)
Q4 20174($0.54)($0.17)($0.36)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Trevena (NASDAQ:TRVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Trevena (NASDAQ:TRVN)
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 64.49%
Insider Trades by Quarter for Trevena (NASDAQ:TRVN)
Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)
Insider Trades by Quarter for Trevena (NASDAQ:TRVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016Carrie L BourdowSVPBuy4,000$4.34$17,360.00View SEC Filing  
11/7/2016Maxine GowenCEOBuy12,500$4.10$51,250.00View SEC Filing  
11/7/2016Yacoub HabibSVPBuy5,000$4.12$20,600.00View SEC Filing  
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08View SEC Filing  
12/10/2015David SoergelCMOSell27,217$10.55$287,139.35View SEC Filing  
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Trevena (NASDAQ:TRVN)
Latest Headlines for Trevena (NASDAQ:TRVN)
Source:
DateHeadline
americanbankingnews.com logo Analysts Anticipate Trevena, Inc. (TRVN) to Post -$0.36 EPS
www.americanbankingnews.com - June 26 at 2:22 PM
finance.yahoo.com logoTrevena Attends National Institutes of Health Meeting to Discuss Development of Novel, Improved Pain Medications
finance.yahoo.com - June 21 at 6:17 AM
americanbankingnews.com logoTrevena Inc (TRVN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 6 at 9:26 AM
americanbankingnews.com logoTrevena Inc (TRVN) Downgraded by ValuEngine
www.americanbankingnews.com - June 2 at 10:30 PM
finance.yahoo.com logoTrevena to Present at Investor Conferences in June
finance.yahoo.com - June 2 at 3:34 PM
finance.yahoo.com logoTrevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - May 31 at 11:20 PM
americanbankingnews.com logo-$0.36 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter
www.americanbankingnews.com - May 31 at 10:28 AM
americanbankingnews.com logoTrevena Inc (TRVN) Price Target Increased to $11.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - May 28 at 8:56 PM
americanbankingnews.com logoShort Interest in Trevena Inc (TRVN) Decreases By 0.7%
www.americanbankingnews.com - May 18 at 4:23 PM
finance.yahoo.com logoTrevena Announces Presentations During the 36th Annual Scientific Meeting of the American Pain Society
finance.yahoo.com - May 17 at 12:34 PM
americanbankingnews.com logoTrevena Inc (TRVN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 9:53 AM
americanbankingnews.com logoTrevena Inc (TRVN) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 8 at 9:36 PM
americanbankingnews.com logoFY2021 EPS Estimates for Trevena Inc (TRVN) Lowered by Analyst
www.americanbankingnews.com - May 8 at 12:28 PM
americanbankingnews.com logoFY2020 EPS Estimates for Trevena Inc Cut by Analyst (TRVN)
www.americanbankingnews.com - May 8 at 12:12 PM
americanbankingnews.com logoTrevena Inc (TRVN) Given a $10.00 Price Target by Oppenheimer Holdings Inc. Analysts
www.americanbankingnews.com - May 7 at 8:02 AM
americanbankingnews.com logoTrevena Inc (TRVN) Earns "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - May 5 at 5:38 PM
americanbankingnews.com logoTrevena Inc (TRVN) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - May 5 at 12:20 PM
americanbankingnews.com logoTrevena Inc (TRVN) Posts Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - May 4 at 10:10 PM
finance.yahoo.com logoTrevena Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 4 at 10:17 AM
finance.yahoo.com logoTrevena reports 1Q loss
finance.yahoo.com - May 4 at 10:17 AM
americanbankingnews.com logoSomewhat Positive News Coverage Somewhat Likely to Impact Trevena (TRVN) Share Price
www.americanbankingnews.com - May 3 at 5:08 PM
finance.yahoo.com logoETFs with exposure to Trevena, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 6:20 PM
americanbankingnews.com logoTrevena Inc (TRVN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - May 1 at 6:22 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Unlikely to Impact Trevena (TRVN) Stock Price
www.americanbankingnews.com - April 30 at 3:05 PM
americanbankingnews.com logoTrevena (TRVN) Receiving Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 27 at 1:04 PM
americanbankingnews.com logoTrevena (TRVN) Earning Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 5:32 PM
americanbankingnews.com logoTrevena (TRVN) Getting Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 9:42 PM
americanbankingnews.com logoTrevena (TRVN) Receiving Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - April 18 at 2:38 PM
americanbankingnews.com logoAegis Reaffirms "Buy" Rating for Trevena Inc (TRVN)
www.americanbankingnews.com - April 17 at 11:16 AM
americanbankingnews.com logoTrevena Inc (TRVN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 17 at 11:07 AM
americanbankingnews.com logoTrevena Inc (TRVN) Research Coverage Started at HC Wainwright
www.americanbankingnews.com - April 15 at 4:52 PM
americanbankingnews.com logoTrevena (TRVN) Given Daily Media Sentiment Rating of 0.07
www.americanbankingnews.com - April 15 at 1:48 PM
americanbankingnews.com logo-$0.53 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter
www.americanbankingnews.com - April 14 at 1:20 PM
streetinsider.com logoTrevena (TRVN) Says Two Posters at ASRA Highlight Positive Phase 3 Data Comparing OLINVO with Intravenous Morphine
www.streetinsider.com - April 7 at 6:08 PM
finance.yahoo.com logoETFs with exposure to Trevena, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 6:08 PM
americanbankingnews.com logoTrevena Inc (TRVN) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - April 5 at 4:09 PM
finance.yahoo.com logoTrevena to Present at Needham & Company’s 16th Annual Healthcare Conference
finance.yahoo.com - March 30 at 6:30 AM
americanbankingnews.com logoTrevena Inc (TRVN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:17 AM
americanbankingnews.com logoTrevena Inc (TRVN) Short Interest Up 46.1% in March
www.americanbankingnews.com - March 26 at 7:05 AM
americanbankingnews.com logoTrevena's (TRVN) Buy Rating Reaffirmed at Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 24 at 10:24 PM
finance.yahoo.com logoWhat Makes Trevena (TRVN) a Strong Sell?
finance.yahoo.com - March 22 at 10:39 PM
americanbankingnews.com logoCowen and Company Reiterates Buy Rating for Trevena Inc (TRVN)
www.americanbankingnews.com - March 22 at 1:43 PM
seekingalpha.com logoBuying Trevena Inc. Could Be A Huge Upside Trade
seekingalpha.com - March 21 at 8:08 PM
americanbankingnews.com logoTrevena Inc (TRVN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 21 at 1:37 PM
americanbankingnews.com logoBrokers Set Expectations for Trevena Inc’s Q1 2017 Earnings (TRVN)
www.americanbankingnews.com - March 16 at 12:19 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trevena, Inc. (TRVN) - PR Newswire (press release)
www.prnewswire.com - March 15 at 10:30 PM
finance.yahoo.com logoTREVENA (TRVN) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Trevena, Inc.; Investors Encouraged to Contact Firm
finance.yahoo.com - March 15 at 10:30 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trevena, Inc. (TRVN)
finance.yahoo.com - March 15 at 10:30 PM
finance.yahoo.com logoINVESTOR ALERT: Investigation of Trevena Announced by Holzer & Holzer, LLC
finance.yahoo.com - March 15 at 8:05 AM
finance.yahoo.com logoTREVENA INC Financials
finance.yahoo.com - March 14 at 7:51 PM

Social

Chart

Trevena (TRVN) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by MarketBeat.com Staff